Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer by Helen Chew et al.
a SpringerOpen Journal
Chew et al. SpringerPlus 2014, 3:108
http://www.springerplus.com/content/3/1/108STUDY PROTOCOL Open AccessPhase II study of lapatinib in combination with
vinorelbine, as first or second-line therapy in
women with HER2 overexpressing metastatic
breast cancer
Helen Kent Chew1*, Lee Schwartzberg2, Suprith Badarinath3, Peter Rubin4, Grace Shumaker5, James Daugherty6,
Michelle DeSilvio7 and Janine Mahoney7Abstract
Background: Lapatinib in combination with capecitabine is approved for the treatment of patients with advanced
or metastatic breast cancer whose tumors overexpress the human epidermal growth factor receptor 2 (HER2) and
who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Based on our phase I trial,
we conducted a single arm, multicenter phase II study of lapatinib in combination with vinorelbine.
Patient and methods: Women with HER2-positive advanced breast cancer, who had received up to one prior
regimen for metastatic disease, were eligible. Prior trastuzumab was allowed. Patients received daily lapatinib
1500 mg orally and vinorelbine 20 mg/m2 intravenously on days 1, 8 and 15 of a 28-day cycle. The primary
endpoint was overall response rate (ORR).
Results: Forty-four patients received the combination treatment, including 48% as second-line therapy. The ORR was
41% (95% confidence interval [CI] 26–55%), including 9% with a complete response. Median progression-free survival
was 24.1 weeks (95% CI 17–37 weeks) and median duration of response was 32 weeks (95% CI 18–42 weeks). Nearly
80% of patients did not require a dose reduction in lapatinib, although most patients required one dose reduction of
vinorelbine secondary to neutropenia. The most common toxicities were grade 1 and 2 diarrhea, nausea, fatigue and
rash, and grade 3 and 4 neutropenia. One case of grade 3 asymptomatic decreased left ventricular ejection fraction
event was reported.
Conclusion: The combination of lapatinib and vinorelbine was active, feasible and well tolerated in patients with
HER2-positive advanced breast cancer.
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The addition of the anti-human epidermal growth factor
receptor 2 (HER2) monoclonal antibody trastuzumab to
chemotherapy improved time to disease progression,
objective response rates and survival in patients with meta-
static, HER2-positive breast cancer compared to chemo-
therapy alone (Slamon et al. 2001). This seminal study
changed the standard of care for HER2 overexpressed or* Correspondence: helen.chew@ucdmc.ucdavis.edu
1Division of Hematology/Oncology, UC Davis Comprehensive Cancer Center,
4501 X Street, Suite 3016, Sacramento, CA 95817, USA
Full list of author information is available at the end of the article
© 2014 Chew et al.; licensee Springer. This is an
Attribution License (http://creativecommons.or
in any medium, provided the original work is pamplified advanced breast cancer and provided rationale
to investigate other targeted therapies in biologically rele-
vant pathways in solid and hematologic malignancies.
Trastuzumab has been combined with many other che-
motherapeutic regimens (Burstein et al. 2001; Marty et al.
2005; Bartsch et al. 2007; Robert et al. 2006). Despite this
progress, most patients will eventually experience disease
progression on trastuzumab.
Lapatinib is an oral small molecule tyrosine kinase in-
hibitor (TKI) that targets the epidermal growth factor
receptor (EGFR) and HER2. In combination with cape-
citabine, a 5-fluorouracil pro-drug, lapatinib improvedOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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alone in patients with advanced HER2-positive breast can-
cer that had progressed on trastuzumab (Geyer et al.
2006). This combination was approved by the US Federal
Drug Administration (FDA) in 2007.
A phase I study of lapatinib in combination with vino-
relbine, a vinca alkaloid microtubule inhibitor, revealed
that the combination was feasible with manageable toxi-
city (Chew et al. 2012). The maximum tolerated dose
was vinorelbine 20 mg/m2 weekly on days 1, 8 and 15
and lapatinib 1500 mg daily on a 28-day cycle. Dose
limiting toxicities included grade 3 infection, febrile neu-
tropenia and diarrhea in this phase I population.
Based on the phase I results, we conducted a multi-
institutional phase II trial of lapatinib and vinorelbine in
patients with HER2-positive advanced breast cancer who
had received up to one prior chemotherapeutic regimen
for metastatic disease.
Patients and methods
This was a single-arm, multi-center, phase II study
(ClinicalTrials.gov NCT00709618) evaluating the effi-
cacy and safety of lapatinib plus vinorelbine in women
with HER2-overexpressing metastatic breast cancer,
who had received no more than one prior chemothera-
peutic regimen in the metastatic setting. The study was
conducted between June 2008 and May 2012 at 17 cen-
ters in the United States.
The study was performed in accordance with the Dec-
laration of Helsinki and approved by the respective insti-
tutional review boards of each participating site. For a
list of institutional review boards which approved this
study, please see additional file 1.
Patients
Eligible patients were women ≥18 years of age who had
histologically confirmed HER2-positive invasive breast
cancer (defined as HER2 amplification [>2.2] by fluores-
cence in situ hybridization or a 3+ positive score by immu-
nohistochemistry) that had progressed after no more than
1 prior chemotherapeutic regimen in the metastatic set-
ting. All prior systemic therapy was completed ≥4 weeks,
and all hormonal therapy ≥1 week, before the first dose of
study treatment. Patients had stage IV disease at primary
diagnosis or at relapse after curative-intent surgery, an
Eastern Cooperative Oncology Group (ECOG) perform-
ance status of 0–2, an estimated survival of ≥12 weeks,
and ≥1 measurable lesion according to Response Eva-
luation Criteria in Solid Tumours (RECIST) guidelines.
Patients were required to have adequate organ and bone
marrow function and a cardiac ejection fraction of at least
50% (measured by echocardiogram [ECHO] or multigated
acquisition scan [MUGA]). Patients with stable central
nervous system metastasis for at least 3 months werepermitted. Bisphosphonate therapy for bone metastases
was allowed, but treatment must have been initiated prior
to the first dose of study medication.
Exclusion criteria included patients with active cardiac,
hepatic, or biliary diseases and diseases or surgeries affect-
ing gastrointestinal function. Patients were excluded if
they had received prior therapy with lapatinib or vinorel-
bine (prior trastuzumab was permitted), were undergoing
concurrent treatment with anticancer or investigational
agents, were pregnant or breastfeeding, or had pre-exis-
ting neuropathy of grade 2 or more.
All patients provided voluntary written informed consent
in accordance with institutional and federal guidelines.
Study design
Patients received oral lapatinib, at 1500 mg once daily,
plus vinorelbine intravenously, 20 mg/m2 on Days 1, 8
and 15, of a 28-day cycle. Granulocyte colony-stimulating
factor (GCSF) was not mandated, but could be used in
accordance with American Society of Clinical Oncology
(ASCO) guidelines (ASCO 2006). Patients continued on
study treatment until disease progression or withdrawal
from study due to unacceptable toxicity, withdrawal of
consent, or lost to follow up.
Efficacy evaluations were performed on all patients at
8-week (±7 days) intervals for the duration of the study,
as well as at the end of all study treatment. Safety assess-
ments were performed on all patients at 4-week (±7 days)
intervals. Assessments of left ventricular ejection frac-
tion (LVEF) by ECHO or MUGA scan were performed
at baseline and q 12 weeks while on study.
Endpoints
The primary efficacy endpoint was overall response rate
(ORR), defined as the percentage of subjects achieving ei-
ther a confirmed complete response (CR; defined as dis-
appearance of all target lesions) or partial response (PR;
defined as at least a 30% decrease in the sum of the lon-
gest diameter [LD] of the target lesion, taking the baseline
sum LD as a reference), based on confirmed responses
from the investigator assessment of best overall response.
Secondary efficacy endpoints included progression-free
survival (PFS; defined as the time from the start of treat-
ment until the earliest date of disease progression or death
due to any cause, if sooner), overall survival (OS; defined
as the time from the start of treatment until death due to
any cause) and duration of response (DoR; defined for the
subset of subjects who showed a confirmed CR or PR, the
time from the first documented evidence of CR or PR
until the first documented sign of disease progression or
death due to any cause, if sooner). Other secondary end-
points included time to response (TTR; defined for the
subset of subjects who showed a confirmed CR or PR, the
time from the start of treatment until first documented




Median (range) 56.0 (29–82)
Race, n (%)
Caucasian/White 32 (73)
African American/African heritage 12 (27)
ECOG status at baseline, n (%)
0 25 (57)
1 19 (43)
HER2 status, n (%)
FISH+ (with or without IHC+) 27 (61)
IHC 3+ (only) 29 (66)
ER/PgR status, n (%)
ER+ and/or PgR+ 23 (52)
ER- and PgR- 21 (48)






Number of prior metastatic chemotherapeutic
regimen (s), n (%)
0 23 (52)
1 21 (48)
Median time since first diagnosis,
months (range)
28.8 (1–126)
Prior anti-cancer therapy, n (%) 43 (98)
Chemotherapy 35 (80)
Immunotherapy 1 (2)
Hormonal therapy 18 (41)
Biologic therapy 35 (80)
Surgery 43 (98)
Radiotherapy 23 (52)
*All patients were female. ECOG, Eastern Cooperative Oncology Group; ER,
estrogen receptor; FISH, fluorescence in situ hybridization; HER2, Human
epidermal growth factor receptor 2; IHC, immunochemistry; PgR,
progesterone receptor.
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to progression (TTP; defined as the time from the start of
treatment until the earliest date of disease progression or
death due to breast cancer, if sooner). Tumour response
and disease progression were based on assessments from
the investigator review of radiological scans and medical
photographs. RECIST guidelines were used to assess cli-
nical activity and disease status.
Safety assessments included physical exam (vital signs,
ECOG performance status), hematology and clinical la-
boratory evaluations, liver and cardiac toxicity, and moni-
toring of adverse events (AEs). All grade 4 AEs were
defined as serious AEs (SAEs) in this protocol, in addition
to those considered life-threatening or resulting in death
or hospitalization.
Statistical analysis
Based on feasibility a total sample size of 60 subjects
was planned for enrolment. This study was not powered
to provide inference testing for the endpoints.
Efficacy and safety analyses were conducted on the
intent-to-treat (ITT) population, comprising all patients
who received at least 1 dose of study drug. All subjects’
data were included in analyses up to the time of with-
drawal. Subjects who were withdrawn prematurely from
the study treatment, but who were not withdrawn from
the study at the same time, were included in the analyses
regardless of the duration of treatment. Subjects with
unknown or missing response were treated as non-
responders and included in the denominator for per-
centage calculation. Exact 95% confidence limits for the
tumor response rates were calculated and no statistical
comparisons were made in the study.
PFS, OS, DoR, TTR, and TTP were summarized using
Kaplan-Meier estimates, along with approximate 95%
confidence interval (CI). Greenwood’s formula was used
to calculate the standard error of the estimate.
Results
Patients
This study was terminated early due to insufficient recruit-
ment. A total of N = 44 patients were enrolled and treated,
approximately one-third of the patients (n = 14, 32%) com-
pleted the study and 25 (57%) withdrew due to study
termination. The most frequent reasons for study treat-
ment discontinuation were disease progression (n = 26,
59%) and decision by subject/proxy (n = 10, 23%).
Patient demographics and disease characteristics are
summarized in Table 1. Over one-quarter of the patient
population was African or African-American. The median
time from initial diagnosis (any stage) was 28.8 months;
48% of the patients had previously received one prior che-
motherapeutic regimen in the metastatic setting. Most pa-
tients (98%) had received prior anti-cancer treatment,primarily surgery. The most common sites of metastatic
disease at baseline were the lungs and lymph nodes,
followed by the liver and bone (Additional file 2: Table S1).
Primary efficacy results - overall tumor response rate
The combination of lapatinib and vinorelbine was asso-
ciated with an investigator-assessed ORR of 41% (n = 18,
95% CI: 26.4, 55.4), with 14 patients (32%) having a PR,
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stable disease (SD) (Table 2).
Secondary efficacy results
The median Kaplan-Meier estimate of investigator-assessed
PFS was 24.1 weeks (95% CI 16.9, 36.7) (Table 2). OS was
not estimated as the data were not mature and the study
had been terminated early with no further data on survival
status collected. A total of 14 patients (32%) had died at
the end of the study. The median Kaplan-Meier estimate
of investigator-assessed TTR and DoR was 7.5 weeks (95%
CI 7.1, 8.1) and 32.0 weeks (95% CI 18.0, 42.3), respec-
tively, for patients who responded (CR or PR). The
Kaplan-Meier estimate for median TTP was 24.1 weeks
(95% CI 16.9, 36.7), which was similar to PFS in this study
as all of the PFS events (either progression or death due to
any cause) were disease progressions.Table 2 Efficacy results (ITT population)
Characteristic Lapatinib + vinorelbine
(N=44)
Investigator assessed Overall Response Rate (ORR)
Overall response rate (CR+PR), n (%) 18 (41)
(95% CI) (26.4, 55.4)
Best response, n (%)
Complete response (CR) 4 (9)
Partial response (PR) 14 (32)
Stable disease (SD) 14 (32)
Progressive disease (PD) 5 (11)
Unknown 7 (16)
Investigator assessed Progression-Free Survival (PFS)
Patients, n (%)
Progressed or died due to any cause * 29 (66)
Censored, follow-up ended 15 (34)
Kaplan-Meier estimate for PFS (weeks)
Median (95% CI) 24.1 (16.9, 36.7)
Time to response (TTR)
Patients, n (%) 18 (100)
Kaplan-Meier estimate for TTR (weeks)
Median (95% CI) 7.5 (7.1, 8.1)
Duration of Response (DoR)
Patients, n (%) 18 (100)
Progressed or died due to any cause 13 (72)
Censored, follow-up ended 5 (28)
Kaplan-Meier estimate for DoR (weeks)
Median (95% CI) 32.0 (18.0, 42.3)
*All deaths were due to breast cancer, therefore progression-free survival and
time to progression (TTP) were the same.
CI, confidence interval.Study treatment exposure
The median duration of exposure to lapatinib was
4.5 months (range, 0–21 months) with a mean daily dose
of 1421.9 mg (Additional file 2: Table S2). In total, 59
lapatinib dose interruptions occurred in 17 patients
(39%). These interruptions were of short duration (49 in-
terruptions were ≤7 days in duration), and were mainly
due to reasons other than hematological toxicities (78%).
Twenty-three reductions in lapatinib dose were made in
10 patients (23%); 4%, 30% and 65% of the reductions
were due to hematological toxicities, non-hematological
toxicities and other reasons, respectively.
In total, 43% of the study population completed at
least 6 cycles of treatment with vinorelbine, which was
the duration of treatment specified in the protocol.
Twenty-five (57%) patients received less than 6 cycles
and 12 patients (27%) continued to receive protocol
therapy beyond 6 cycles. Thirty reductions in the dose of
vinorelbine were made in 26 patients (59%), and were
mainly due to hematological toxicities (87%). Twenty
five doses of vinorelbine were delayed in 15 patients
(34%), and were most commonly due to hematological
toxicity (40%) and reasons other than non-hematological
toxicity (44%).
Safety
The most commonly reported AEs were diarrhea, neutro-
penia, fatigue, nausea, and rash (Table 3). The maximum
toxicity grade of the majority of the most commonly re-
ported AEs was grade 2 or 3. The most frequent grade 3
AEs experienced by patients were neutropenia (16%) and
diarrhea (11%). A single case of grade 3 asymptomatic de-
crease in LVEF was reported.
A total of 16 patients (36%) experienced grade 4 AEs
(neutropenia, febrile neutropenia and hyperglycemia) but
only neutropenia and febrile neutropenia were considered
treatment-related. AEs of neutropenia reached a maxi-
mum toxicity grade 4 for 15 patients (34%) (Table 3). Of
the 30 patients that experienced any grade neutropenia/
febrile neutropenia, only 12 patients received GCSF
support.
All SAEs experienced by patients are presented in
Table 4. No fatal SAEs were reported during the study.
Two subjects withdrew from study treatment due to
AEs (peripheral neuropathy and nausea).
Discussion
In a study population in which 48% of patients were re-
ceiving second-line therapy for metastatic, HER2-positive
breast cancer, the combination of lapatinib and vino-
relbine led to a 41% ORR, including a 9% CR rate. A
randomized phase II trial comparing lapatinib and vinorel-
bine with lapatinib and capecitabine (VITAL study) re-
ported the primary endpoint of PFS of 6.2 months in each
Table 3 AEs by Maximum Toxicity Grade (ITT population)
Adverse events Lapatinib + vinorelbine (N=44)
Number of subjects, n (%)
Total Grade 1 Grade 2 Grade 3 Grade 4
Common AEs with >15% incidence
Diarrhea 36 (82) 22 (50) 9 (20) 5 (11) 0
Neutropenia 29 (66) 1 (2) 6 (14) 7 (16) 15 (34)
Nausea 27 (61) 17 (39) 8 (18) 2 (5) 0
Fatigue 23 (52) 13 (30) 8 (18) 2 (5) 0
Rash 22 (50) 12 (27) 9 (20) 1 (2) 0
Constipation 15 (34) 10 (23) 5 (11) 0 0
Vomiting 14 (32) 8 (18) 5 (11) 1 (2) 0
Hypokalaemia 12 (27) 8 (18) 2 (5) 2 (5) 0
Anaemia 11 (25) 4 (9) 6 (14) 1 (2) 0
Insomnia 11 (25) 7 (16) 4 (9) 0 0
Abdominal pain 10 (23) 4 (9) 4 (9) 2 (5) 0
Decreased appetite 10 (23) 6 (14) 4 (9) 0 0
Dehydration 8 (18) 0 5 (11) 3 (7) 0
Back pain 8 (18) 5 (11) 3 (7) 0 0
Dyspepsia 8 (18) 6 (14) 2 (5) 0 0
Mucosal inflammation 7 (16) 2 (5) 4 (9) 1 (2) 0
Neutrophil count decreased 7 (16) 1 (2) 6 (14) 0 0
Pain in extremity 7 (16) 4 (9) 3 (7) 0 0
Pyrexia 7 (16) 5 (11) 2 (5) 0 0
Cough 7 (16) 6 (14) 1 (2) 0 0
AEs of special interest
Hepatobiliary events 5 (11) 3 (7) 1 (2) 1 (2) 0
Febrile neutropenia* 3 (7) 0 0 1 (2) 2 (5)
Interstitial lung disease 0 0 0 0 0
Cardiac events 1 (2) 0 0 1 (2) 0
AE, adverse event; ITT, intent-to-treat.
*2/3 patients reporting febrile neutropenia are also counted among the 29 patients reporting neutropenia.
Table 4 Serious adverse events (SAEs)
Lapatinib + vinorelbine (N=44)
Subjects with any SAE, n (%) 22 (50)
With ≥2 (5%) patients, n (%)
Neutropenia 15 (34)*
Diarrhea 3 (7)
Febrile neutropenia 3 (7)
Abdominal pain 2 (5)
Dehydration 2 (5)
Drug-related fatal SAEs, n (%) 0 (0)
*Grade 4 laboratory abnormalities were protocol defined as SAEs.
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study (Janni et al. 2012). Both phase II trials had similar
patient populations, but different schedules and dosing of
lapatinib and vinorelbine. The current results are compar-
able to ORRs of 22% and 31%, respectively, with the com-
bination of lapatinib and capecitabine in two other trials
(Geyer et al. 2006; Verma et al. 2012). In those trials, pa-
tients were required to have had prior therapy with trastu-
zumab and anthracyclines and/or taxanes (in the adjuvant
or metastatic setting). Furthermore, in a more heavily pre-
treated population that had progressed on trastuzumab,
the combination of lapatinib and trastuzumab was asso-
ciated with a survival benefit over lapatinib alone and an
ORR of 10% (Blackwell et al. 2010).
In the current trial, grade 4 toxicities included neutro-
penia (34%), febrile neutropenia (7%) and hyperglycemia
(2%). The most common grade 3 toxicities included
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and nausea, fatigue, rash, hypokalemia and abdominal
pain (each 5%). There was one case of grade 3 asymp-
tomatic decrease in LVEF. Similar incidence of grades 3
and 4 neutropenia were reported in the VITAL trial with
15% of participants discontinuing treatment (Janni et al.
2012). Nearly 80% of patients did not require a dose re-
duction of lapatinib in the current trial. Of the patients
who had a dose reduction, the majority (18 of 23) had
only one reduction. A greater percentage of patients
(59%) required dose reduction of vinorelbine, due mainly
to neutropenia and associated with dose delays. Of the
30 patients with any grade neutropenia/febrile neutro-
penia, only 12 patients received GCSF support. These
results suggest that the combination of lapatinib and
vinorelbine is a potential treatment option for patients
with HER2-positive advanced breast cancer who have
had up to one prior chemotherapeutic regimen for meta-
static disease.
At the initiation of this trial, lapatinib was the only
therapeutic option for HER2-positive disease after progres-
sion on trastuzumab. Continued HER2-directed therapy,
with either trastuzumab or lapatinib, despite progression
on trastuzumab, was associated with improvements in
time to disease progression compared to chemotherapy
alone in two phase III trials (Geyer et al. 2006; von
Minckwitz et al. 2009). The activity in this phase II trial,
similar to the VITAL trial, provides patients with ad-
ditional combination options with lapatinib. Since the start
of this trial, other lapatinib combinations have been re-
ported. Lapatinib and paclitaxel improved time to progres-
sion compared to paclitaxel alone in a subset of patient
with metastatic HER2-positive breast cancer (Di Leo et al.
2008). Likewise, lapatinib and the aromatase inhibitor
letrozole improved progression-free survival in postmeno-
pausal women with hormone receptor positive and HER2-
positive metastatic breast cancer compared to letrozole
alone (Johnston et al. 2009). This endocrine therapy and
lapatinib combination was approved by the FDA in 2010.
Since the completion of this trial, other therapies for
HER2-positive breast cancer have been approved. Pertu-
zumab, a monoclonal antibody that binds to a region of
the HER2 protein distinct from trastuzumab, has been
approved as first-line therapy for metastatic HER2-
positive disease in combination with trastuzumab and
docetaxel (Baselga et al. 2012) and as neoadjuvant treat-
ment with a similar regimen (Gianni et al. 2012). The
drug antibody conjugate, TDM-1, has been approved
for patients who have previously received trastuzumab
(Verma et al. 2012).
The therapeutic landscape for HER2-positive meta-
static breast cancer has advanced in the last decade to
include three additional FDA-approved agents beyond
trastuzumab. The optimal treatment sequence, the rolesof these agents in the adjuvant and neoadjuvant settings,
and the significance of trastuzumab resistance will be ex-
plored in ongoing and future clinical trials.
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